Skip to main content
Journal ArticleOPEN ACCESS

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

  • Gerstein H
  • Sattar N
  • Rosenstock J
  • et al.
New England Journal of Medicine (2021) 385(10) 896-907
DOI: 10.1056/nejmoa2108269
347Citations
Citations of this article
260Readers
Mendeley users who have this article in their library.

Abstract

Abstract Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular events among per...

Cite

CITATION STYLE

APA

Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., … Branch, K. (2021). Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 385(10), 896–907. https://doi.org/10.1056/nejmoa2108269

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free